Coompo Research Chemicals

Oridonin inhibited growth of multiple myeloma (MM; U266, RPMI8226), acute lymphoblastic T-cell leukemia (Jurkat), and adult T-cell leukemia (MT-1) cells with an effective dose that inhibited 50% of target cells (ED50) ranging from 0.75 to 2.7 μg/ml. oridonin inhibited nuclear factor-κB (NF-κB) DNA-binding activity in these cells as measured by luciferase reporter gene, ELISA-based, and electrophoretic mobility shift assays. Oridonin also blocked tumor necrosis factor-α– and lipopolysaccharide-stimulated NF-κB activity in Jurkat cells as well as RAW264.7 murine macrophages. Oridonin did not affect survival of normal lymphoid cells from healthy volunteers. Taken together, oridonin might be useful as adjunctive therapy for individuals with lymphoid malignancies, including the lethal disease adult T-cell leukemia.Oridonin has been proved to possess remarkable anticancer activity, in addition to its potential in antiinflammation and antibacteria.

Oridonin was shown to be a potent apoptosis inducer in a variety of cancer cells. However, whether oridonin can be used in the selected setting of hematology/oncology, and which types of hematologic malignancies could represent the most sensitive ones to oridonin treatment, remain obscure.